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INTRODUCTION: Pemphigoid gestationis, also known as herpes gestationis, is a rare autoimmune blistering disease associated 
with pregnancy. It usually occurs during the second or third trimester, but it may be present at any stage of pregnancy or the puer-
perium. The clinical, histologic, and immunopathological features of pemphigoid gestationis are similar to those of the pemphigoid 
group of disorders. 
METHODS: We hereby report seven patients who were diagnosed with pemphigoid gestationis and followed at the Autoimmune 
Blistering Disease Clinic in the Department of Dermatology of the University of Sao Paulo Medical School between 1996 and 
2008. DISCUSSION: Demographic and clinical findings, such as median age, sites of involvement, and gestational age of onset 
of our patients, coincide with those described in previous reports. The majority of patients (85%) exhibited complement C3 or C3 
and immunoglobulin G (IgG) deposition along the basement membrane zone (BMZ) on immunofluorescence. Herpes gestationis 
factor (HG) factor was postitive in four out of six patients (67%), and three out of five patients recognized the bullous pemphigoid 
recombinant antigen (BP180) by ELISA. 
CONCLUSION: This study revealed a good outcome of the newborns from pemphigoid gestationis affected mothers, based on 
the absence of pemphigoid gestationis cutaneous lesions, mean birth weight, and normal Apgar scores and gestational age at birth. 
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INTRODUCTION
Pemphigoid gestationis (PG), also known as herpes 
gestationis, is a rare autoimmune blistering disease 
associated with pregnancy. It usually occurs during the 
second or third trimester of pregnancy, but it may be 
present at any stage of pregnancy or during the puerperium. 
It has an estimated incidence of 1 in 50,000 (general 
population) worldwide. Its clinical, histopathologic, and 
immunopathological features are similar to those of the 
pemphigoid group of blistering disorders. PG and bullous 
pemphigoid (BP) auto-antibodies bind to a common 
antigenic site within the non-collagenous domain (NC16A) 
of the transmembrane 180 kDa BP2 antigen.1-3
Classically, PG presents as erythematous urticarial 
plaques that can subsequently develop into tense blisters. 
The periumbilical area is usually the first site involved. 
Pruritus is an important symptom associated with the onset 
of disease.1
We report on seven patients who were diagnosed with 
pemphigoid gestationis and followed at the Autoimmune 
Blistering Disease Clinic in the Department of Dermatology 
of the University of Sao Paulo Medical School between 
1996 and 2008, focusing on their clinical, histological, and 
immunopathological features. 
METHODS 
We reviewed the records of PG patients who were 
diagnosed with pemphigoid gestationis and followed at 
the Autoimmune Blistering Disease Clinic, Department 
of Dermatology, University of São Paulo Medical School 1044
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between 1996 and 2008. Demographic data (age), clinical 
features including timing of disease onset, site of lesions, 
and symptoms (pruritus) were analyzed, and laboratory 
evaluation, included histological examination, direct and 
indirect immunofluorescence techniques (DIF and IIF), 
with the complement fixation test (herpes gestationis factor), 
and enzyme-linked immunosorbent assay (ELISA) for the 
detection of anti BP-180 antibodies).
RESULTS
Demographic Data and Clinical Presentations
Seven cases of PG were diagnosed in our department 
between 1996 and 2008, and the patient age ranged from 19 
to 39 years (mean, 30.3 years). Disease onset was reported 
in the second trimester of pregnancy in four patients and 
in the third trimester of pregnancy in three patients. One 
patient had a flare up of symptoms during the puerperium. 
Main sites of involvement were lower limbs (mainly thighs), 
forearms, trunk, and abdomen (Figure 1). One patient had 
initial lesions that resembled erythema multiforme on her 
palms and soles. None of the patients had facial or mucosal 
lesions. Pruritus was the main complaint in all patients. 
No history of associated autoimmune disorders (such as 
Grave’s disease) or malignancies was present in any patient. 
Five patients developed the disease after previous normal 
pregnancies and two had PG during their first pregnancy. 
One of the latter had three subsequent pregnancies also 
affected by the disease. There was no mention in her chart 
of a worsening of her clinical features or an earlier onset of 
her symptoms in each subsequent pregnancy as described in 
the literature. 
Demographic, clinical, and treatment data are compiled 
in Table 1.
Histopathological and Immunofluorescence Findings
The histopathologic (HE) and immunofluorescence (IF) 
findings are presented in Table 2.
Subepidermal bullae with eosinophilic infiltrates 
(Figure 2) were found in three out of the six patients who 
underwent histopathological evaluation, and inflammatory 
eosinophilic infiltrates were found at the dermis in the other 
three patients. DIF staining revealed linear C3 deposition 
along the BMZ in four out of seven patients (Figure 3). 
Two patients exhibited linear C3 and IgG deposits along the 
BMZ and one patient exhibited linear IgM deposits along 
the BMZ. 
The HG factor (indirect complement-added IF) was 
positive in four out of six patients. Two umbilical cord 
blood samples were collected at the time of delivery for 
each subject, and circulating IgG anti-BP180 antibodies 
were found in one sample. Five patients underwent ELISA 
testing for the presence of anti-BP180, and three out of 
Figure 1 - Pemphigoid Gestationis: Pruritic urticarial lesions and tense 
blisters on the trunk Figure 2 -   Pemphigoid Gestationis: Histopathology (HE): subepidermal 
bulla with eosinophils (X40)1045
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five patients tested positive for anti-BP180 and had high 
titers. The assayed sample from one of the patients that was 
negative for the presence of anti-BP180 by ELISA had been 
collected five years after delivery, whereas the other samples 
were collected while the patients had active disease.
Evaluation of the Newborns
The Apgar scores and weights of the newborns were 
available in six out of seven PG patients’ charts. None of 
them had low Apgar scores (defined as below a minimum 
score of eight at the first minute of life and below a 
minimum score of nine at the tenth minute of life). Only 
one newborn had low birth weight, but the mother had 
other clinical disorders (gestational diabetes and essential 
hypertension) that might have affected the birth weight. 
One newborn was premature (35 weeks of pregnancy) due 
Table 1 - Pemphigoid gestationis: demographic, clinical and treatment data
Patient Age 
(years)
Obstetric history Previous affected 
pregnancies
Onset of 
symptoms
Sites of involvement Treatment Remission of lesions
1 33 IVG IIP IIA − 2nd trimester Trunk, abdomen, upper 
arms and legs
Prednisone Two months after    
delivery
2 19 IIG IIP 0A − 2nd trimester Trunk, abdomen,  upper 
arms and legs
Prednisone 15 days after delivery. 
Pre menstrual 
exacerbations for 6 
months.
3 23 IG IP 0A − 3rd trimester Abdomen, thighs, trunk, 
upper arms, legs, palms 
and soles
Prednisone 45 days after delivery
(Flare up after birth)
4 32 IIG IIP 0A − 3rd trimester Upper arms, trunk, 
abdomen and thighs
Prednisone and 
azathioprine
One year after delivery
5 35 VG VP 0A − 3rd trimester Trunk, abdomen, and legs Prednisone After birth, follow up 
not available
6 31 IIIG IIIP 0A − 2nd trimester Abdomen, upper arms 
and legs
Prednisone One month after 
delivery
7 39 VIIG VP IIA + 
All previous pregnancies,   
except for the two first 
trimester abortions
2nd trimester Trunk, abdomen, upper 
arms and legs
Only topical 
corticosteroids 
and antihistaminic 
agents
After birth, follow up  
not available
Table 2 - Pemphigoid gestationis: histopathology, direct immunofluorescence, indirect complement-added imunofluorescence 
(HG factor) and BP180 ELISA results (cutoff index ELISA:  ≥ 9)
Patient Histopathology DIF HG factor Elisa BP180
1 Subepidermal bulla with eosinophilia C3  + Not performed
2 Eosinophilic inflammatory infiltrate at the dermis C3 and IgG + + (70)
3 Subepidermal bulla with eosinophilia C3 and IgG + − (out of activity)
4 Not available C3 − + (184)
5 Subepidermal bulla with eosinophilia C3 Not performed Not performed
6 Eosinophilic inflammatory infiltrate at the dermis C3 − −
7 Eosinophilic inflammatory infiltrate at the dermis. IgM + + (130)
Figure 3 - Pemphigoid Gestationis:  Direct immunofluorescence of peri-
lesional skin, showing linear deposition of complement (C3) along the 
BMZ (X40)1046
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to chorioamnionitis secondary to early amniorrhexis. None 
of the newborns had PG lesions.
Treatment 
Systemic corticosteroids (prednisone, initial dose: 0.5-1.0 
mg/kg/day) were administered to six out of the seven patients. 
Each patient was treated for as long as active lesions were 
observed. Corticosteroids were gradually withdrawn after 
the lesions had cleared. One patient reported premenstrual 
exacerbations while withdrawing from corticosteroids. 
Mild topical corticosteroids and antihistaminic agents were 
necessary to control symptoms in only one patient. Six out 
of seven patients had complete remission by two months 
after delivery. Only one patient had a prolonged course of 
the disease: she achieved complete remission one year after 
delivery. Of note, she was the only patient that received 
adjuvant immunosuppressant therapy (azathioprine 2 mg/kg/
day), which was initiated after she had finished breast feeding.
DISCUSSION
PG is a rare autoimmune pregnancy-associated blistering 
disease. Pathogenesis of PG involves the production of 
auto-antibodies, mainly of the IgG1 subclass, that bind to 
the extracellular NC16A domain of the carboxyl terminus 
of the 180 kDa bullous pemphigoid antigen (BPAg2). Once 
bound, the antigen-antibody complex fixes complement 
via the classical complement pathway. Complement 
activation leads to chemotaxis of eosinophils to the site of 
the antigen-antibody complex on the BMZ. Once there, 
the eosinophils degranulate, and are thought to damage the 
dermal-epidermal junction, leading to blister formation. The 
initiating immunological event that stimulates this immune 
response remains unknown.5
The  clinical  presentation  and  course  of  PG  is 
variable. Most cases remit in the first several weeks after 
delivery. Exacerbations have been documented during 
subsequent pregnancies, during menstruation, and with oral 
contraceptive use.1,5,6 
Our demographic and clinical results (e.g., median 
age, sites of involvement, and gestational age at onset) are 
similar to those described by other authors.1-6 It is important 
to highlight that, in our study no infants were affected by 
PG lesions. The newborns born to PG-affected mothers had 
good outcomes in this study; the mean birth weights, Apgar 
scores, and gestational age at birth of these infants were all 
normal. A review of the recent literature revealed findings 
similar to those of our study: there is not an increase in 
maternal or fetal morbidity in mothers with PG.1-5
One of the most important conditions from which PG 
must be differentiated is polymorphic urticarial papules 
and plaques of pregnancy (PUPPP).2,7 PUPPP is a pruritic 
eruption of unknown etiology and resembles non-bullous 
PG. Differentiation between PG and PUPPP depends on 
demonstration of the presence of anti-BMZ auto-antibodies 
by immunofluorescence, immunoblotting, or ELISA 
in patients with PG. The precise diagnosis of these two 
conditions is relevant, once PUPPP is usually treated with 
topical emollients and corticosteroids, poses no risk to the 
newborn, and rarely recurs during future pregnancies,6,7 
whereas PG often requires systemic treatment, may affect 
the newborn, and often recurs (as high as 92% of the time) 
during subsequent pregnancies,1 with possible earlier onset 
of the disease and worsening of the clinical symptoms.1 
In light of this, correct diagnosis is important to allow for 
early control of the disease and appropriate counseling of 
the mother regarding her course of treatment and risk of 
developing PG during future pregnancies. 
DIF staining is the preferred method for routine 
diagnosis of PG.2 Serological analysis, including testing 
for the presence of HG factor and BP180 ELISA, played 
a key role in the diagnosis of one patient in our evaluation. 
Previous studies have similarly described the clinical utility 
of serological analysis. Recent findings have demonstrated 
the high sensitivity and specificity of BP180 ELISA tests for 
diagnosing PG.7-9 Aoyama et al.10 described an association 
between BP180 ELISA titers and disease severity as well 
as the important role that anti-BP180 titers may play in 
therapeutic planning. 
Regarding treatment, the majority of our patients were 
controlled with high doses of systemic corticosteroids. 
One patient received azathioprine due to the chronic course 
of her disease, and the lesions lasted for over one year. 
Prolonged courses of PG,11-14 as well as transformation of 
the disease into BP 15 have been described. Many attempts 
to differentiate chronic PG from BP have been made: PG is 
associated with HLA DR3 and DR4, while BP is associated 
with HLA-DQ3.2,16,17 In addition, a higher prevalence of C3 
over IgG deposition along the BMZ indicates the presence 
of PG.16 However, the differential diagnosis between the two 
conditions is often difficult.
Brazil is a country known as endemic for pemphigus 
foliaceus, which suggests an environmental role in the 
pathogenesis of this cutaneous blistering autoimmune 
disease. Therefore, the behavior of other autoimmune 
blistering diseases, such as PG in this country is relevant. 
Our study revealed that demographic data, clinical 
presentation, laboratory findings, and treatment of our PG 
patients shared many similarities with many other studies 
performed worldwide, indicating that environmental triggers 
are seldom related to the pathogenesis of PG.1047
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